Effects of serotonin 5‐HT1A agonist in advanced Parkinson's disease
Identifieur interne : 003937 ( Main/Curation ); précédent : 003936; suivant : 003938Effects of serotonin 5‐HT1A agonist in advanced Parkinson's disease
Auteurs : William Bara-Jimenez [États-Unis] ; Francesco Bibbiani [États-Unis] ; Michael J. Morris [États-Unis] ; Tzvetelina Dimitrova [États-Unis] ; Abdullah Sherzai [États-Unis] ; Maral M. Mouradian [États-Unis] ; Thomas N. Chase [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-08.
English descriptors
- KwdEn :
- 5‐HT1A receptor, Aged, Antiparkinson Agents (therapeutic use), Dose-Response Relationship, Drug, Double-Blind Method, Drug Evaluation (methods), Female, Humans, Male, Middle Aged, Organic Chemicals, Parkinson Disease (drug therapy), Parkinson's disease, Serotonin 5-HT1 Receptor Agonists, Severity of Illness Index, Treatment Outcome, dopamine, dyskinesias, levodopa, serotonin, striatum.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents.
- drug therapy : Parkinson Disease.
- methods : Drug Evaluation.
- Aged, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Organic Chemicals, Serotonin 5-HT1 Receptor Agonists, Severity of Illness Index, Treatment Outcome.
Abstract
Intermittent stimulation of striatal dopaminergic receptors seems to contribute to motor dysfunction in advanced Parkinson's disease (PD). With severe dopaminergic denervation, exogenous levodopa is largely decarboxylated to dopamine in serotonergic terminals. If 5‐HT1A autoreceptors regulate dopamine as well as serotonin release, in parkinsonian patients inhibition of striatal serotonergic neuron firing might help maintain more physiological intrasynaptic dopamine concentrations and thus ameliorate motor fluctuations and dyskinesias. To evaluate this hypothesis, effects of a selective 5‐HT1A agonist, sarizotan, given orally at 2 and 5 mg twice daily to 18 relatively advanced parkinsonian patients, were compared with baseline placebo function during a 3‐week, double‐blind, placebo‐controlled, proof‐of‐concept study. Sarizotan alone or with intravenous levodopa had no effect on parkinsonian severity. But at safe and tolerable doses, sarizotan coadministration reduced levodopa‐induced dyskinesias and prolonged its antiparkinsonian response (P ≤ 0.05). Under the conditions of this study, our findings suggest that 5‐HT1A receptor stimulation in levodopa‐treated parkinsonian patients can modulate striatal dopaminergic function and that 5‐HT1A agonists may be useful as levodopa adjuvants in the treatment of PD. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20370
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002407
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :002407
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002347
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003097
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :003097
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003149
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001204
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :001204
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001204
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :005024
Links to Exploration step
ISTEX:5344FB0941453C52FC59B0697C4054DC8A6E6412Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of serotonin 5‐HT1A agonist in advanced Parkinson's disease</title><author><name sortKey="Bara Imenez, William" sort="Bara Imenez, William" uniqKey="Bara Imenez W" first="William" last="Bara-Jimenez">William Bara-Jimenez</name></author><author><name sortKey="Bibbiani, Francesco" sort="Bibbiani, Francesco" uniqKey="Bibbiani F" first="Francesco" last="Bibbiani">Francesco Bibbiani</name></author><author><name sortKey="Morris, Michael J" sort="Morris, Michael J" uniqKey="Morris M" first="Michael J." last="Morris">Michael J. Morris</name></author><author><name sortKey="Dimitrova, Tzvetelina" sort="Dimitrova, Tzvetelina" uniqKey="Dimitrova T" first="Tzvetelina" last="Dimitrova">Tzvetelina Dimitrova</name></author><author><name sortKey="Sherzai, Abdullah" sort="Sherzai, Abdullah" uniqKey="Sherzai A" first="Abdullah" last="Sherzai">Abdullah Sherzai</name></author><author><name sortKey="Mouradian, Maral M" sort="Mouradian, Maral M" uniqKey="Mouradian M" first="Maral M." last="Mouradian">Maral M. Mouradian</name></author><author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5344FB0941453C52FC59B0697C4054DC8A6E6412</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20370</idno><idno type="url">https://api.istex.fr/document/5344FB0941453C52FC59B0697C4054DC8A6E6412/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002407</idno><idno type="wicri:Area/Istex/Curation">002407</idno><idno type="wicri:Area/Istex/Checkpoint">002347</idno><idno type="wicri:doubleKey">0885-3185:2005:Bara Imenez W:effects:of:serotonin</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15791634</idno><idno type="wicri:Area/PubMed/Corpus">003097</idno><idno type="wicri:Area/PubMed/Curation">003097</idno><idno type="wicri:Area/PubMed/Checkpoint">003149</idno><idno type="wicri:Area/Ncbi/Merge">001204</idno><idno type="wicri:Area/Ncbi/Curation">001204</idno><idno type="wicri:Area/Ncbi/Checkpoint">001204</idno><idno type="wicri:doubleKey">0885-3185:2005:Bara Jimenez W:effects:of:serotonin</idno><idno type="wicri:Area/Main/Merge">005024</idno><idno type="wicri:Area/Main/Curation">003937</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effects of serotonin 5‐HT1A agonist in advanced Parkinson's disease</title><author><name sortKey="Bara Imenez, William" sort="Bara Imenez, William" uniqKey="Bara Imenez W" first="William" last="Bara-Jimenez">William Bara-Jimenez</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Bibbiani, Francesco" sort="Bibbiani, Francesco" uniqKey="Bibbiani F" first="Francesco" last="Bibbiani">Francesco Bibbiani</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Morris, Michael J" sort="Morris, Michael J" uniqKey="Morris M" first="Michael J." last="Morris">Michael J. Morris</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Dimitrova, Tzvetelina" sort="Dimitrova, Tzvetelina" uniqKey="Dimitrova T" first="Tzvetelina" last="Dimitrova">Tzvetelina Dimitrova</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Sherzai, Abdullah" sort="Sherzai, Abdullah" uniqKey="Sherzai A" first="Abdullah" last="Sherzai">Abdullah Sherzai</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Mouradian, Maral M" sort="Mouradian, Maral M" uniqKey="Mouradian M" first="Maral M." last="Mouradian">Maral M. Mouradian</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-08">2005-08</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="932">932</biblScope><biblScope unit="page" to="936">936</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">5344FB0941453C52FC59B0697C4054DC8A6E6412</idno><idno type="DOI">10.1002/mds.20370</idno><idno type="ArticleID">MDS20370</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>5‐HT1A receptor</term><term>Aged</term><term>Antiparkinson Agents (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Evaluation (methods)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Organic Chemicals</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson's disease</term><term>Serotonin 5-HT1 Receptor Agonists</term><term>Severity of Illness Index</term><term>Treatment Outcome</term><term>dopamine</term><term>dyskinesias, levodopa</term><term>serotonin</term><term>striatum</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Evaluation</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Organic Chemicals</term><term>Serotonin 5-HT1 Receptor Agonists</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Intermittent stimulation of striatal dopaminergic receptors seems to contribute to motor dysfunction in advanced Parkinson's disease (PD). With severe dopaminergic denervation, exogenous levodopa is largely decarboxylated to dopamine in serotonergic terminals. If 5‐HT1A autoreceptors regulate dopamine as well as serotonin release, in parkinsonian patients inhibition of striatal serotonergic neuron firing might help maintain more physiological intrasynaptic dopamine concentrations and thus ameliorate motor fluctuations and dyskinesias. To evaluate this hypothesis, effects of a selective 5‐HT1A agonist, sarizotan, given orally at 2 and 5 mg twice daily to 18 relatively advanced parkinsonian patients, were compared with baseline placebo function during a 3‐week, double‐blind, placebo‐controlled, proof‐of‐concept study. Sarizotan alone or with intravenous levodopa had no effect on parkinsonian severity. But at safe and tolerable doses, sarizotan coadministration reduced levodopa‐induced dyskinesias and prolonged its antiparkinsonian response (P ≤ 0.05). Under the conditions of this study, our findings suggest that 5‐HT1A receptor stimulation in levodopa‐treated parkinsonian patients can modulate striatal dopaminergic function and that 5‐HT1A agonists may be useful as levodopa adjuvants in the treatment of PD. © 2005 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003937 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 003937 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Curation
|type= RBID
|clé= ISTEX:5344FB0941453C52FC59B0697C4054DC8A6E6412
|texte= Effects of serotonin 5‐HT1A agonist in advanced Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |